In parallel, we also demonstrate that decitabine, an FDA-approved anti-cancer drug, reactivates endogenous cGAS expression by reversing epigenetic silencing and subsequently elicits anti-tumor activity in ecDNA+ tumors. The gene discussed is CGAS; the disease is neoplasm.